Matuzumab Biosimilar, EGFR Monoclonal Antibody

Matuzumab Biosimilar uses the same protein sequences as the therapeutic antibody matuzumab. Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human epidermal growth factor receptor (EGFR)
Clone	Matuzumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	145.5 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4